瘢痕性类天疱疮及新出现的治疗方法的最新进展

Update on ocular cicatricial pemphigoid and emerging treatments.

作者信息

Queisi Munther M, Zein Mike, Lamba Neerav, Meese Halea, Foster Charles Stephen

机构信息

Massachusetts Eye Research and Surgery Institution, Waltham, Massachusetts, USA; Ocular Immunology and Uveitis Foundation, Waltham, Massachusetts, USA.

Massachusetts Eye Research and Surgery Institution, Waltham, Massachusetts, USA; Ocular Immunology and Uveitis Foundation, Waltham, Massachusetts, USA; Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, USA.

出版信息

Surv Ophthalmol. 2016 May-Jun;61(3):314-7. doi: 10.1016/j.survophthal.2015.12.007. Epub 2015 Dec 19.

DOI:10.1016/j.survophthal.2015.12.007

PMID:26708362

Abstract

Mucous membrane pemphigoid is a systemic disorder that primarily affects mucous membranes. When localized to the conjunctiva, it is known as ocular cicatricial pemphigoid, a potentially blinding disease. Ocular cicatricial pemphigoid is an indication for systemic immunosuppressive treatment to achieve adequate remission. Immunosuppressive agents are selected with a "stepladder" approach, commencing with medications having the fewest side effects. We provide an update of the literature on immunomodulatory agents since 2011 as additional treatment modalities have been explored in the last 4 years.

摘要

黏膜类天疱疮是一种主要累及黏膜的全身性疾病。当局限于结膜时，它被称为瘢痕性类天疱疮，是一种有潜在致盲风险的疾病。瘢痕性类天疱疮是进行全身免疫抑制治疗以实现充分缓解的指征。免疫抑制剂的选择采用“阶梯式”方法，从副作用最少的药物开始。自2011年以来，随着在过去4年中探索了更多的治疗方式，我们提供了关于免疫调节药物的文献更新。